Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kuemmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Zhu Y, Pan W, Tryfonidis K, Karantza V, O'Shaughnessy J (2022)
Publication Type: Conference contribution
Publication year: 2022
Publisher: WILEY
City/Town: HOBOKEN
Pages Range: 117-118
Conference Proceedings Title: ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
APA:
Schmid, P., Cortes, J., Dent, R., Pusztai, L., Mcarthur, H., Kuemmel, S.,... O'Shaughnessy, J. (2022). Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (pp. 117-118). HOBOKEN: WILEY.
MLA:
Schmid, Peter, et al. "Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522." Proceedings of the ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY HOBOKEN: WILEY, 2022. 117-118.
BibTeX: Download